Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New combination treatment for hepatitis C reported more beneficial than standard therapy

27.09.2002


he New England Journal of Medicine’s Sept. 26 issue carries the first published report showing that a combination treatment with peginterferon alfa-2a (Pegasys) - a new long-acting interferon drug - and an antiviral medication is more beneficial than the standard combination therapy for people with the most-difficult-to-treat and most common strain of hepatitis C.



The large international study, headed by researchers at the University of North Carolina at Chapel Hill, is also the first published one to show that treatment with the investigational drug peginterferon alfa-2a in combination with the oral antiviral medication, ribavirin, is linked to a lower rate of troublesome side effects - depression, flu-like symptoms (chills, headache and fever) - than the standard interferon (Rebetron) and ribavirin.

"Sixty-five percent of patients in the study were infected with hepatitis C genotype 1, the most prevalent genotype we see here in the United States, and typically the least responsive to therapy," said study co-author Dr. Michael W. Fried, associate professor of medicine and director of clinical hepatology at the UNC School of Medicine.


"With this research, we’ve found the most significant evidence to date suggesting these patients might benefit by taking peginterferon alfa-2a in combination with ribavirin."

According to Fried, side effects of therapy can be very challenging for patients. "The study shows an approach that can offer patients superior efficacy without increases in some of the most common and difficult to tolerate adverse events associated with hepatitis C therapy."

Of the six different strains, or genotypes, of hepatitis C, approximately 70 percent of people in North America are infected with genotype 1.

The study was funded by Hoffmann-La Roche, the maker of Pegasys, and was conducted at 81 clinical sites in 18 countries. More than 1,100 patients were involved in one of three study arms: 453 were treated with peginterferon alfa-2a plus oral ribavirin, 224 with peginterferon alfa-2a plus placebo and 444 with interferon alfa-2b plus ribavirin. Patients were treated for 48 weeks and then monitored for an additional 24 weeks.

A key variable measured by the study was sustained viral response, defined as undetectable serum hepatitis C RNA after the treatment-free follow-up period.

Overall, patients treated with the peginterferon alfa-2a plus ribavirin combination achieved a 56 percent sustained response rate as compared to patients taking Rebetron (44 percent). Patients with genotype 1 had a sustained response rate of 46 percent, compared to patients on Rebetron (36 percent) and those on Pegasys plus placebo (21 percent).

A retrospective analysis of the data showed that response to PEG interferon alpha-2a plus ribavirin is predictable. At week 12, 86 percent of patients treated with PEG interferon demonstrated an early viral response; of these, 65 percent attained a sustained viral response. However, 97 percent of patients who did not respond by week 12 failed to achieve a sustained response.

"This means that physicians can create an alternate treatment plan for patients who do not show any response by week 12," said Fried. "And for those who do respond, it can be a motivation to continue to adhere to their treatment regimens."

Dr. Fried added that these treatment decisions must be individualized for each patient.

The hepatitis C virus is a life-threatening viral infection of the liver transmitted primarily through infected blood and blood products. Approximately 2.7 million Americans and 170 million people worldwide are chronically infected with the virus, which is often described as "silent" because people may be infected for 10 to 30 years and not exhibit symptoms, yet still be carrying the virus.

While many patients with the hepatitis C virus will not develop complications from their liver disease, chronic hepatitis C is still a leading cause of cirrhosis and liver cancer and is the major indication for liver transplants in this country.

The UNC Center for Liver Diseases and Transplantation provides highly specialized care for liver diseases for residents of North Carolina and surrounding regions. In addition to its commitment to patient care, the UNC liver program is dedicated to studying novel therapies for viral hepatitis, other chronic liver diseases and transplantation.


Contact note: Fried is available at (919) 966-8784 or mfried@med.unc.edu

Leslie Lang | EurekAlert!
Further information:
http://www.med.unc.edu/

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>